Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

CEO Letter: Updates on BSI and Last Months' Activities

I am happy to share our four key CS MEDICA updates, demonstrating our commitment to resilience and market expansion.  ISO 13485 Certification Progress Last week, we completed the second audit stage for the ISO 13485 certification with the notified body, BSI. This critical milestone underscores our dedication to the highest quality, safety, and compliance standards—vital for European medical device companies. The thorough audit reassured us that we are aligned with the path to the new, stricter medical device regulations. We are actively working on the audit's actions and developing

CANNORDIC India Ltd., a CS MEDICA Subsidiary, Signs Letter of Intent with the Pharmaceutical Company Zuventus Healthcare to Launch CANNASEN® in India

The Partnership Projects Up to €15 Million Revenue from Innovative CBD-infused Medical Devices by Year Three Post-Registration.CANNORDIC India Ltd., under the umbrella of CS MEDICA Group, has signed a Letter of Intent (LOI) with Zuventus Healthcare Ltd., a premier pharmaceutical company in India. This agreement marks the initial engagement towards establishing a preferred partnership for distributing and marketing the CANNASEN® brand within the medical device category across India. The partnership will focus on addressing autoimmune diseases and stress-related disorders. The

CS MEDICA Achieves MDR Classification, Setting New Standards in Substance-Based Medical Devices

Leading Healthcare Innovation with Stringent ComplianceCS MEDICA, a pioneer in MedTech specializing in pain management, autoimmune diseases, and stress-related disorders, has reached a significant regulatory milestone: · Class IIa Classification: Confirmed under Europe's Medical Device Regulation (MDR) for 3 substance-based medical devices with CBD under Rule 21. · Notified Body: A certification by BSI, the notified body (authority) that defines the classification and certifies the products, underscoring our stringent compliance and market readiness.  Responding to Consumer

CS MEDICA Pioneers CBD-Infused Medical Devices in Jordan with Confirmed Classification

Newly classified products set to boost market presence with an initial order of 100,000 units in Jordan and anticipated positive influence across the MENA region.CS MEDICA is pleased to announce a progression in its collaboration within Jordan, following the confirmed classification of its core portfolio as medical devices with cannabidiol (CBD). This development aligns with Jordan's recent regulatory framework that allows products with low THC concentrations in the market. This is a progressive step for the region, especially within the Middle Eastern and North African (MENA) territories

CS MEDICA Q3 2023/2024: Growth Through Strategic Regulatory and Market Adaptations

Navigating Complex Markets with Innovations Leads to a 400% Increase in Revenue Year-to-Date and an Expansive Global Reach, Supported by a Robust mDKK 49.3 Order Pipeline.CS MEDICA, a Danish MedTech leader specializing in pain management, autoimmune diseases, and stress-related disorders, announced achieving a year-to-date revenue growth of over 400%, totaling mDKK 4.6, complemented by an additional order intake of mDKK 49.3. As revenue recognition occurs post-product delivery and invoicing in markets where our medical devices must be approved for sale by regulatory authorities, the lead

CS MEDICA Q3 2023/2024 Results: Strong Revenue Growth of 400% Despite Production Delays

Revenue Grew Over 400% Year-to-Date, and Order Intake Hit mDKK 49.3, Fueled by Strategic Partnerships and ExpansionCS MEDICA, a Danish MedTech leader specializing in pain management, autoimmune diseases, and stress-related disorders, reports its financial performance for the third quarter of 2023/2024 (April–June 2024). In a display of resilience and strategic insight, CS MEDICA met its Q3 revenue target despite facing production delays that necessitated carrying over mDKK 1.5 million to the next quarter. The company delivered mDKK 0.5 in net sales this quarter, achieving a robust year-to-

CS MEDICA's CANNORDIC Names Pharma Avanti as Preferred Partner in Brazil

Pioneering Access to Innovative Pain Relief and CBD Solutions and Gateway to South AmericaCS MEDICA A/S announces a new distribution partnership with Pharma Avanti, designated as the preferred partner for its subsidiary, CANNORDIC, in Brazil. This alliance signals a strategic move into Brazil's growing pain relief and CBD market and positions Brazil as a gateway for expanding into the broader South American market. Highlighting the financial impact of this partnership, CANNORDIC has secured an initial order post-regulation 327 approval with ANVISA, consisting of 50,000 units, spanning

CS MEDICA's Subsidiary, CANNORDIC, Signs Distributor Partnership with PHARMALINK

Expanding Access to Innovative Healthcare Solutions in the UAECS MEDICA A/S, a pioneering MedTech company specializing in innovative substance-based medical devices containing bioactive CBD, announces a new distributor partnership between its subsidiary, CANNORDIC, and PHARMALINK, a reliable partner with a strong footprint established over 30 years in the United Arab Emirates (UAE). This collaboration introduces CANNORDIC's 9 products under the CANNASEN® brand across the UAE market through Pharmalink’s own extensive marketing, distribution and retail network, enhancing healthcare options

Press Release: CS MEDICA's View of the Evolving European CBD Market

Strategic Investments in Compliance and Evidence-Based Treatments to Drive GrowthCS MEDICA, a Danish MedTech pioneer focusing on pain management, autoimmune disease, and stress-related disorders, highlights the importance of compliance and evidence-based treatments in the CBD market. With the European CBD market projected to reach €1.97 billion by 2024, regulatory challenges and demand for scientifically backed products are shaping the industry.  Market Overview The European CBD market faces fragmented regulations and slow Novel Food authorizations in the EU and UK, creating

CS MEDICA A/S: Minutes of Extraordinary General Meeting

CS MEDICA Approves Key Proposals at Extraordinary General MeetingCS MEDICA (”CS MEDICA” or “The Company”) is pleased to announce the successful approval of several key proposals at its Extraordinary General Meeting (EGM) held on July 31, 2024.  The approved resolutions are as follows: 1. Election of Chairman of the Meeting · Flemming Heegard was elected as the chairman of the meeting. 2. Capital Increase for Remuneration of IR Agreement · The shareholders approved a capital increase of 317,000 shares at DKK 3.00 per share, without pre-emption rights for existing

CS MEDICA A/S Evaluates Pre-IPO Share Distribution for CANNORDIC Stock Spin-off

CS MEDICA Aims to Strengthen Shareholder Bonds with Pre-IPO Share Distribution for CANNORDIC in GermanyCS MEDICA A/S, a pioneering MedTech company specializing in innovative substance-based medical devices containing bioactive CBD, announced on June 10, 2024, its plans to spin off stocks and list its subsidiary CANNORDIC A/S on the German Stock Market (Intention to Float). Today, the company announces its evaluation of the possibility of distributing CANNORDIC shares to existing CS MEDICA shareholders ahead of the planned initial public offering (IPO) in 2024, approved at the

CS MEDICA Leverages Strategic Partnerships for CANNASEN® Brand Launch in APAC and MENA

Launching 36,000 Units to Test Market Fit and Accelerate Market Penetration at a value of €419,000CS MEDICA announces an advancement in its expansion strategy with the upcoming launch of CANNASEN® in the Asia-Pacific (APAC) and Middle East/North Africa (MENA) regions. This launch utilizes strong partnerships and a Minimum Viable Product (MVP) approach to establish the CANNASEN® brand. CS MEDICA will distribute 36,000 units of CANNASEN® to APAC and MENA at a value of €419,000 starting August 2024. This initiative aims to gather consumer insights to perfect product alignment and readiness

CS MEDICA Receives "Intention To Grant" for European Patent Application Concerning CANNASEN® Psoriasis Gel, Reinforcing Leadership in CBD-infused Dermatological Innovations

Innovative Approach to Compliant Psoriasis Treatment Aims for Patent ProtectionCS MEDICA is proud to announce the receipt of an "Intention To Grant" for its patent application from the European Patent Organization (EPO), which has 39 member states[1]. This achievement enhances the protection of its innovative product, CANNASEN® Psoriasis Gel, which contains CBD. This patent discloses a novel treatment approach for psoriasis symptoms such as pain, itch, redness, scaling, and inflammation, along with the specific composition of the psoriasis gel. Psoriasis, an immune-mediated disorder,

CS MEDICA A/S Secures Repurchase Orders from Key European Partners

CANNORDIC Continues Momentum with Recurring Orders of 45.000 Units from European Healthcare LeadersCS MEDICA, a pioneering MedTech company specializing in pain management and autoimmune diseases with innovative substance-based medical devices containing bioactive CBD, announces that its subsidiary, CANNORDIC, has received repurchase orders for 45,000 units from its German partner, Alsitan, and Spanish partner, Uriach, for delivery in Q3 and Q4, 2024. CANNORDIC hereby strengthens its market penetration with a total of 241,000 units in orders from the two leading European Healthcare

CS MEDICA Announces Strategic Partnerships to Enhance Funding

Securing New Capital and Strengthening Shareholder Relations Through Strategic CollaborationsCS MEDICA, a pioneering MedTech company specializing in pain management and autoimmune diseases with innovative substance-based medical devices containing bioactive CBD, announces a direct issue of 1.5 MDKK with Börsjakten AB at a share price of 3.00 DKK. This initiative is part of our broader strategy to secure short-term capital while preparing for a larger funding round, pending approval at the upcoming EGM. Additionally, we are excited to unveil three strategic collaborations aimed at enhancing

CS MEDICA A/S: Notice of Extraordinary General Meeting

The shareholders of CS MEDICA A/S ("CS MEDICA" or the "Company") are hereby notified of an Extraordinary General Meeting to be held on Wednesday 31, 2024, at 09:00 at TEAMS.Proposed agenda 1. Election of chairman of the meeting 2. Proposal to make a capital increase of 317.000 shares for DKK 3,00 per share without pre-emption right for the existing shareholders. The capital increase can be subscribed by Börsjakten AB or companies/persons related to Börsjakten AB, including its investor network. The shares are offsetting a remuneration for an IR agreement amounting to SEK 1.450.000.

CS MEDICA Stock Now Also Traded on XETRA

Enhanced Liquidity and Trading Opportunities for ShareholdersCS MEDICA (“CS MEDICA” or “The Company”), a MedTech pioneer specializing in pain management and autoimmune diseases with innovative substance-based medical devices containing bioactive CBD, has been trading on the Frankfurt Stock Exchange since March 2, 2023. The company is now pleased to announce that its shares are also available on Deutsche Börse AG's XETRA trading platform, facilitated by the private bank Hauck Aufhäuser Lampe. Deutsche Börse AG imposes stringent criteria on Designated Sponsors for liquidity provision.

CS MEDICA: CEO Insights on Achievements and Future Plans

Q&A on German IPO, Structural Enhancements, and Growth Strategies.Q&As from the CEOI want to reflect on our recent achievements and outline structural enhancements based on the EGM resolution. I'll detail how we aim to build resilience to secure future growth and increase shareholder value. It may be a lengthy summary, but based on the questions and pitches we receive, it's essential to provide complete insight into our plans and intentions for business growth.  1. REFINED COMPANY STRUCTURE We've streamlined our group structure to enhance operational efficiency, meet new EU

CS MEDICA A/S: Minutes of Extraordinary General Meeting

Today on June 28, 2024, in Copenhagen - CS MEDICA A/S (”CS MEDICA” or “The Company”) held an extraordinary general meeting at which the following principal resolutions were passed.Authorization for the company's board of directors to list CS MEDICA shares on the German Stock Exchange. The Extraordinary General Meeting (EGM) resolved in accordance with the Board of Directors’ proposal to authorize the company's board of directors to list the company on one of the multilateral trading facilities (MTF) in Germany. Authorization for the company's board of directors to list the company's

CS MEDICA Group Completes Product Registration of CANNASEN® CBD-Infused Medical Devices in Israel

Strategic Milestone Achieved as CANNORDIC, a CS MEDICA Subsidiary, Navigates Regulatory ChallengesCS MEDICA Group, a forerunner in innovative substance-based medical devices containing bioactive CBD, announces the successful completion of the product registration process for the entire CANNASEN® portfolio of CBD-infused medical devices in Israel. This achievement marks a regulatory milestone for our subsidiary, CANNORDIC, and sets a new standard for over-the-counter CBD products in the region. The first product, the CANNASEN® Pain Patch, received approval from Israel's Ministry of Health

CS MEDICA Announces Strategic Partnership with OneMed

CS MEDICA Signs with OneMed for Enhanced Distribution and Marketing in DenmarkCS MEDICA is happy to announce a new strategic partnership with OneMed, a leading distributor in the healthcare sector. This collaboration marks a significant step in CS MEDICA's newly adopted B2B2C strategy, which focuses on generating strategic partnerships for enhanced market access while continuing to prioritize its core values in research and development, production, compliance, and insights. As part of the Asker Group, OneMed brings a robust distribution network and a deep understanding of the medical

Strategic Expansion through Innovation and Collaboration

CS MEDICA A/S Announces Strategic Letter of Intent with GP Europe Holding B.V.CS MEDICA A/S ("CS MEDICA"), a first mover in the development of Cannabidiol (CBD)-infused substance-based medical devices, announces the signing of a Letter of Intent (LOI) with GP Europe Holding B.V. ("GP Holding"), a distinguished entity in the hemp product sector based in Rotterdam, Netherlands. This LOI marks the preliminary step towards establishing a potentially transformative partnership focused on supply chain enhancement and distribution agreements, paving the way for possible investment or merger

CS MEDICA A/S: Notice of Extraordinary General Meeting

The shareholders of CS MEDICA A/S ("CS MEDICA" or the "Company") are hereby notified of an Extraordinary General Meeting to be held on Friday, June 28[th] 2024 at 10:00 AM via TEAMS.CS MEDICA is convening this Extraordinary General Meeting (EGM) to discuss and approve key strategic initiatives, including the listing of shares on the German Stock Exchange and the IPO of its wholly-owned subsidiary, CANNORDIC A/S. Proposed Agenda: 1. Authorization for Listing - Authorization for the company's board of directors to list CS MEDICA shares on the German Stock Exchange. 2. Subsidiary IPO -

CS MEDICA Plans Stock Spin-Off and Listing of CANNORDIC

CS MEDICA A/S, a pioneering MedTech company specializing in innovative substance-based medical devices containing bioactive CBD, today announced its plans to spin off and list its subsidiary CANNORDIC A/S on the German Stock Market (Intention to Float).CS MEDICA ("CS MEDICA" or "The Company") aims to elevate the value of CS MEDICA's shares, targeting a preliminary valuation of CANNORDIC of MDKK 224. This is a Compliant Publication according to Article 17 MAR of Regulation (EU) No 596/2014. The Board Members of CS MEDICA, with ISIN DK0061668225, announced the approval to spin off its

There are no items matching the current filter
There are no more items matching the current filter
Back to top